Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06934226 · ClinicalTrials.gov registry record · Phase 3
A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
A Phase 3 study of Plaque Psoriasis, sponsored by Janssen Research & Development.
- Active
- Registry status
- Phase 3
- Development phase
- 752
- Enrollment target
- 20
- Study locations
NCT06934226: Active Phase 3 study of Plaque Psoriasis, sponsored by Janssen Research & Development.
NCT06934226 is a Phase 3 study of Plaque Psoriasis that is active but no longer recruiting, run by Janssen Research & Development. The registered enrollment target is 752 participants, above the 399-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (88% higher). The trial reports 20 study locations across 9 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT06934226, a Phase 3 study of Plaque Psoriasis, is active but no longer recruiting, sponsored by Janssen Research & Development.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 752 participants
- Enrollment target
- 20
- Study locations
Study Summary
The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.
Primary Outcome
IGA score is given based on the investigator's assessment of the participant's plaque psoriasis at a given time point. Overall lesions are graded for induration, erythema, and scaling. The participant's plaque psoriasis is assessed as: cleared (0), minimal (1), mild (2), moderate (3), or severe (4).
Conditions Studied
Interventions
- DRUG Ustekinumab
- DRUG JNJ-77242113
- DRUG Matching Placebo to JNJ-77242113
- DRUG Matching Placebo to Ustekinumab
Study Locations (20)
California
- California Dermatology & Clinical Research Institute - Encinitas
- T Joseph Raoof Md Inc - Encino
- First OC Dermatology - Fountain Valley
- Dermatologist Medical Group of North County, Inc. - Oceanside
- NorCal Clinical Research - Rocklin
- Integrative Skin Science and Research - Sacramento
- MedDerm Associates - San Diego
- Southern California Dermatology - Santa Ana
- Olive View-UCLA Education & Research Institute - Sylmar
Florida
- Driven Research LLC - Coral Gables
- Bioclinical Research Alliance Inc. - Miami
- Renstar Medical Research - Ocala
- Forcare Clinical Research Inc - Tampa
Alabama
- Cahaba Research Inc - Birmingham
Connecticut
- University of Conn Health Center - Farmington
Georgia
- Hamilton Research LLC - Alpharetta
Illinois
- Northshore Medical Group - Skokie
Indiana
- Indiana Clinical Trial Center - Plainfield
Iowa
- University of Iowa - Iowa City
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 752 participants |
| Start Date | 2025-04-15 |
| Est. Completion | 2027-08-20 |
| Phase | Phase 3 |
What the registry record for NCT06934226 still lists
NCT06934226 is an interventional study that assigns participants to a tested intervention. The registered 752 participants enrollment target is mid-sized for trials with a published cap, above the 399-participant average among 45 other Plaque Psoriasis trials with a reported enrollment target (88% higher).
The record links to 1 condition, with Plaque Psoriasis appearing as the primary indexed condition, and to 4 interventions - of which Ustekinumab is the first listed.
NCT06934226 names 20 study sites across 9 states, led by California, Florida, Alabama.
Frequently Asked Questions
What is clinical trial NCT06934226 about?
NCT06934226 is a clinical study titled "A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis". The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.
What is the current status of trial NCT06934226?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 752 participants. The study started on 2025-04-15. Estimated completion is 2027-08-20.
What conditions does trial NCT06934226 study?
This clinical trial studies the following conditions: Plaque Psoriasis.
What interventions are being tested in trial NCT06934226?
The interventions under investigation include: Ustekinumab (DRUG), JNJ-77242113 (DRUG), Matching Placebo to JNJ-77242113 (DRUG), Matching Placebo to Ustekinumab (DRUG).
Who is sponsoring clinical trial NCT06934226?
This trial is sponsored by Janssen Research & Development, which has 593 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT06934226 being conducted?
This trial has 20 study locations across Alabama, California, Connecticut, Florida, Georgia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Plaque Psoriasis
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT06934226's enrollment target sits among peer trials
752 9th of 45 higher than 37 of 45 other Plaque Psoriasis trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Plaque Psoriasis trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
Long-Term Safety Study of Deucravacitinib Versus Ustekinumab in Participants With Psoriasis (PRAGMATYK)
RECRUITING · Phase 3
-
A Long-Term Study of Zasocitinib in Children and Teenagers With Plaque Psoriasis
RECRUITING · Phase 3
-
A Study to Evaluate the Efficacy, Safety, and Drug Levels of Deucravacitinib (BMS-986165) in Adolescent Participants With Moderate to Severe Plaque Psoriasis
RECRUITING · Phase 3
-
Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis
ACTIVE NOT RECRUITING · Phase 3
-
A Study of JNJ-77242113 for the Treatment of Participants With Plaque Psoriasis Involving Special Areas (Scalp, Genital, and/or Palms of the Hands and the Soles of the Feet)
ACTIVE NOT RECRUITING · Phase 3
-
Tapinarof for the Treatment of Plaque Psoriasis in Pediatric Subjects
ACTIVE NOT RECRUITING · Phase 3
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT06559306 · 752 participants · Phase 3
Phase 3 Study of Adjunctive Treatment With Seltorexant in Adult and Elderly Participants With Major Depressive Disorder and Insomnia Symptoms
- NCT05379985 · 754 participants · Phase 1
Study of RMC-6236 in Patients With Advanced Solid Tumors Harboring Specific Mutations in RAS
- NCT05427370 · 754 participants · NA
The Canadian CABG or PCI in Patients With Ischemic Cardiomyopathy Trial (STICH3C)
- NCT02048332 · 750 participants · Phase 1
Donor-Derived Viral Specific T-cells (VSTs)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI